January 26, 2017

Medical Therapy for Uterine Fibroids Draws Nearer as Phase 2 Trial Brings Promising Results

16-OBG-2344-Bradley-650×450

By Linda Bradley, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Women with large uterine fibroids suffer with many quality-of-life issues, including limitations on work, travel, hobbies and sexuality. Unfortunately, our treatment options are primarily surgical ‒ hysterectomy or myomectomy. There is a real need for medical options to help these patients, and Cleveland Clinic recently participated in a Phase 2 placebo-controlled dose-related trial (ASTEROID 1) to investigate the progesterone receptor modulator vilaprisan (Bayer Pharma AG) for this purpose. The study was sponsored by Bayer Pharma AG.

As a physician and principal investigator, I looked at this trial with hope and dreams that it could help us add to our toolbox for giving these patients relief. While vilaprisan is still several years away from being ready for “prime time,” the findings from this trial were encouraging.

In ASTEROID 1 (Assess safety and efficacy of vilaprisan in women with uterine fibroids), 309 women age 18 to 50 years of age (mean age, 42) were randomly assigned to one of four vilaprisan doses, 0.5, 1, 2 and 4 mg, or placebo, for a 12-week treatment period, with a 24-week follow-up period. Study participants had to have at least one uterine fibroid of 3-10 cm in diameter and be experiencing heavy menstrual bleeding (at least 80 mL monthly; mean blood loss was 173 mL).

In addition to ultrasound and magnetic resonance imaging of fibroids, the study analyzed laboratory findings and endometrial biopsies. Participants also recorded their impressions of any changes in their condition in electronic diaries and submitted their pads and tampons for analysis of blood quantity.

Advertisement

This was a large multicenter trial, held at 98 sites across 12 countries. This is significant because different cultures can have different views of how women react to pain, discomfort and bleeding. Also, we know that the burden of disease is not the same across all groups. For example, women from the African diaspora tend to experience both earlier onset and comparatively larger fibroids than others.

Results

Overall, investigators were pleased with the results. Up to 40 percent reductions in fibroid size were documented, an effect that was partially sustained during follow up.

Patients reported feeling much better or very much better on the medication, especially those on the higher doses (1, 2 or 4 mg). There were very few adverse events, and no effects on the endometrium in terms of cancer or pre-cancer.

At doses ≥ 1 mg, the majority of patients achieved amenorrhea (< 2 mL/28 days) within 6 days; 87-92 percent achieved it by the end of the treatment course. Most non-placebo patients saw a reduction in their fibroid size during treatment, especially those on the higher doses.

Advertisement

I saw some patients experience dramatic improvement in their symptoms over the course of this study, some of whom I have treated for years. I know how much they have suffered with their condition. Many of them are very eager to have access to the medication again and hope they will be allowed to participate in Phase 3 trials, which are expected to begin early in 2017.

We hope to participate in those trials as well and learn more about which patients are most suited for this treatment. Does it work better in whites than blacks? These and other details will be important information for physicians to have as we seek to provide relief to this patient population.

Related Articles

woman with milk and lettuce
February 14, 2024
Neighborhood Factors Affect Early Pregnancy Metabolic Health

Deprivation is linked to impaired glucose intolerance and racial disparities

23-WHI-4386458 &#8211; OGI &#8211; CQD &#8211; topical treatment for VIN
November 30, 2023
Trial Shows Promise for Topical Treatment for VIN

Artesunate ointment is safe well and tolerated patients with vulvar intraepithelial neoplasia

contraception
June 15, 2023
Update on Current Contraceptive Options

A case-based discussion of efficacy, eligibility and use

OB/GYN Residents Wellness
January 13, 2022
Wellness Efforts Are Needed by OB-GYN Residents, But One Solution Does Not Fit All

Workshop curriculum was valued by some, while others would have preferred time for themselves

Cecile Ferrando MD
June 1, 2021
Pain in Transgender Men Undergoing Hysterectomy

Study finds lower incidence of endometriosis than in cisgender patients

18-OBG-1364-DesaiAccessBlastocyst-650&#215;450
September 23, 2020
Uninterrupted Culture in Time-Lapse Incubator Supports Human Embryonic Development

Large randomized study compares embryo growth kinetics and live birth rates between culture media

20-WHI-1938960 CQD WHI &#8211; Outcomes of Vaginoplasty Surgery &#8211; Ferrando_CQD Hero_650x450
August 27, 2020
Gender-Affirming Vaginoplasty: Reducing Complications

Surgeon experience is key to reducing adverse events

20-WHI-1878668-CQD-Predicting-Early-Pregnancy-Loss_Detti_CQD_650x450_A
April 23, 2020
Predicting Early Pregnancy Loss: Insights from Early, Serial Ultrasounds in Pregnancy

Introducing Laura Detti, MD, newly appointed Chair of the Department of Subspecialty Care for Women’s Health

Ad